Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional)
ID: 346749Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/346749

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-125.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Avenir Award Program for Research on Substance Use Disorders and HIV, aimed at supporting early-stage investigators proposing innovative studies that address critical health issues at the intersection of substance use and HIV/AIDS. This grant program encourages applications that align with NIH HIV/AIDS research priorities and seeks to foster groundbreaking research that could optimize therapies for individuals at risk for HIV due to substance use, ultimately aiming to improve health outcomes in vulnerable populations. Eligible applicants include a diverse range of institutions, and grants can provide up to $375,000 per year for a maximum of four years, totaling $1.5 million, with applications due by August 15, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-125-Full-Announcement.html
    PAR-23-125.html
    The Avenir Award Program, overseen by the National Institutes of Health (NIH) and specifically through the National Institute on Drug Abuse (NIDA), is designed to support early-stage investigators proposing innovative research at the intersection of Substance Use Disorders (SUD) and HIV. This funding opportunity encourages applications that describe the nexus of these two critical health issues and align with NIH HIV/AIDS research priorities. The program aims to foster groundbreaking approaches that could lead to optimizing therapies for individuals using substances and minimize the impact of comorbidities related to HIV. Eligible applicants include various higher education institutions, nonprofits, and government entities. Grants will provide up to $375,000 per year for a maximum of four years, totaling $1.5 million, with awards contingent upon available NIH funding and proposal merit. The program encourages diverse and creative research to address significant challenges in HIV treatment and prevention, especially in populations at risk for HIV due to substance use. Key application elements include a detailed research strategy focusing on the project's significance, innovation, and the investigator's qualifications. Overall, this initiative seeks to promote high-impact research critical for improving health outcomes among vulnerable populations.
    Similar Opportunities
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, a federal grant opportunity aimed at supporting innovative research proposals that address the intersection of HIV/AIDS and substance use disorders. This program seeks to fund exceptionally creative scientists who can propose high-impact studies that diverge significantly from existing research paths, with a focus on transformative approaches to prevention and treatment. The grant provides funding of up to $700,000 annually for a maximum duration of five years, with a submission deadline of August 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1), aimed at supporting early-stage investigators in conducting innovative research in the field of substance use disorders. This funding opportunity encourages applications for high-impact projects that do not require preliminary data, thereby fostering novel approaches to understanding and treating addiction. With a total budget of $3 million available annually over three fiscal years (FY 2024 - FY 2026), each award can provide up to $300,000 per year for a maximum of five years. Interested applicants must submit their proposals by August 9, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the official announcement link: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-007.html.
    Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Avenir Award Program for early-stage investigators focused on the genetics or epigenetics of substance use disorders (SUDs). This grant program aims to support innovative research that has the potential to significantly advance the understanding of addiction, particularly for those researchers who may lack preliminary data typically required for larger grants. The funding opportunity, which totals up to $300,000 annually for a maximum of five years, encourages applications from a diverse range of eligible institutions, including historically underrepresented groups. Interested applicants can submit their proposals until September 25, 2025, and should refer to the full announcement for detailed submission guidelines and requirements, available at NIH Grants. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory studies focused on the mechanisms of HIV infection, replication, latency, and pathogenesis in the context of substance use disorders (SUDs). This initiative aims to support high-risk, high-impact research that utilizes innovative tools to investigate the interactions between HIV and addictive substances, with a particular emphasis on understanding the molecular mechanisms involved and the effects of these substances on HIV latency and replication. The total funding budget for this opportunity is $2 million, intended to support three awards, each capped at $700,000 in direct costs annually. Applications are due by July 14, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-011.html.
    Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at supporting exploratory research into the neuroimmune connections related to HIV and substance use disorders. This initiative seeks to identify and characterize neuroimmune networks and communication pathways, as well as discover novel modulatory tools that can enhance understanding of the regulatory mechanisms contributing to the comorbidity of HIV and substance use disorders. The NIH intends to allocate up to $2 million to fund approximately six awards, with individual budgets not exceeding $275,000 over a two-year period. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.